Spasticity

Current Treatment Options in Neurology

Volumn 11, Issue 3, 2009, Pages 153-161

  Brashear, Allison ^a   Lambeth, Kelly ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; FLUMAZENIL; ORAL CONTRACEPTIVE AGENT; PHENOL; TIZANIDINE;

AGITATION; ASSISTIVE TECHNOLOGY DEVICE; CAREGIVER; CERVICAL DYSTONIA; CLINICAL TRIAL; CONFUSION; CORNEA OPACITY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ELECTROSTIMULATION; EPILEPSY; FOCAL SPASTICITY; GAIT; GLUCOSE BLOOD LEVEL; HALLUCINATION; HUMAN; HYPERTENSION; INJECTION SITE PAIN; JAUNDICE; KIDNEY DYSFUNCTION; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; MUSCLE HYPERTONIA; MUSCLE TONE; NECROSIS; NEUTROPENIA; OCCUPATIONAL THERAPY; OUTCOME ASSESSMENT; PATIENT MONITORING; PERCEPTION DEAFNESS; PERSONAL HYGIENE; PHYSIOTHERAPY; POSTOPERATIVE ANALGESIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; QUALITY OF LIFE; RETINA DEGENERATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SPASTICITY; SPLINT; SURGICAL TECHNIQUE; VASCULAR DISEASE; WEAKNESS;

EID: 64549134638     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0018-4     Document Type: Review

References (36)

1. Gracies JM, Elovic E, Zorowitz R, et al.: Traditional pharmacologic treatments for spasticity. Part II: Systemic treatments. In Etiology, Evaluation, Management and the Role of Botulinum Toxin. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:79-110.
2. Barnes MP: Principles of neurological rehabilitation. J Neurol Neurosurg Psychiatry 2003, 74(Suppl4): Iv3-iv7.
3. Meythaler JM, McCary A, Hadley MN: Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: A preliminary report. J Neurosurg 1997, 87:415-419.
4. Ward AB: A summary of spasticity management - a treatment algorithm. Eur J Neurol 2002, 9(Suppl 1):48-52.
5. Brashear A, McAfee AL, Kuhn ER, Ambrosius WT: Treatment with botulinum toxin type B for upper-limb spasticity. Arch Phys Med Rehabil 2003, 84:103-107.
6. Brashear A, Gordon MF, Elovic E, et al.: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002, 347:395-400.
7. SimpsoB DM, Gracies JM, Graham HK, et al.: Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691-1698.
8. Childers MK, Brashear A, Jozefczyk P, et al.: Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004, 85:1063-1069.
9. Simpson DM, Alexander DN, O'Brien CF, et al.: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996, 46:1306-1310.
10. Gordon MF, Brashear A, Elovic E, et al.: Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004, 63:1971-1973.
11. Bakheit AM, Pittock S, Moore AP, et al.: A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001, 8:559-565.
12. Bakheit AM, Sawyer J: The effects of botulinum toxin treatment on associated reactions of the upper limb on hemiplegic gait - a pilot study. Disabil Rehabil 2002, 24:519-522.
13. Brashear A, Zafonte R, Corcoran M, et al.: Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002, 83:1349-1354.
14. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995, 59:562.
15. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM: Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000, 69:217-221.
16. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA: Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996, 61:30-35.
17. Bakheit AM, Fedorova NV, Skoromets AA, et al.: The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004, 75:1558-1561.
18. Katz RT, RymerMWZ: Spastic hypertonia: mechanisms and measurement. Arch Phys Med Rehabil 1989, 70:144-155.
19. Pandyan AD, CouSins E, van WF, et al.: Spasticity research: some common catches. Arch Phys Med Rehabil 2005, 86:845-846.
20. Mayer N, Esquenazi A, Childers MK: Common patterns of clinical motor dysfunction. In Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:27-38.
21. Bakheit AM, Thilmann AF, Ward AB, et al.: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000, 31:2402-2406.
22. Katz RT: Management of spasticity. Am J Phys Med Rehabil 1988, 67:108-116.
23. Allergan I. Package insert, BOTOX (Botulinum toxin Type A Purified Neurotoxin Complex). Irvine, CA: Allergan, Inc. 2000.
24. Physicians' Desk Reference. Available at http://pdr.net/druginformation. Accessed November 2008.
25. U.S. Food and Drug Administration: Early Communication about an Ongoing Safety Review: Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). Available at http://www.fda.gov/CDER/ Drug/early_comm/botulinium_toxins.htm. Accessed February 17, 2009.
26. Comella CL, Jankovic J, Shannon KM, et al.: Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005, 65:1423-1429.
27. Brashear A: BotuliAum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Investig Drugs 2001, 10:2191-2199.
28. Brashear A, McAfee AL, Kuhn ER, Fyffe J: Botulinum toxin type B in upper-limb poststroke spasticity: A double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004, 85:705-709.
29. Brashear A, Lew MF, Dykstra DD, et al.: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999, 53:1439-1446.
30. Ward AB: Long-term modification of spasticity. J Rehabil Med 2003, 41(Suppl):60-65.
31. Coffey RJ, Edgar TS, Francisco GE, et al.: Abrupt withdrawal from intrathecal baclofen: Recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002, 83:735-741.
32. Botte MJ, Abrams RA, Bodine-Fowler SC: Treatment of acquired muscle spasticity using phenol peripheral nerve blocks. Orthopedics 1995, 18:151-159.
33. Gracies JM, Elovic E, Zorowitz R, et al.: Traditional pharmacologic treatments for spasticity. Part 1: Local treatments. In Etiology, Evaluation, Management and the Role of Botulinum Toxin. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:57-78.
34. McGuire JR: Effective use of chemodenervation and chemical neurolysis in the management of poststroke spasticity. Top Stroke Rehabil 2001, 8:47-55.
35. Pill S, Keenan M: Neuro-orthopedic management of extremity dysfunction in patients with spasticity from upper motor neuron syndromes. In Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome. Edited by Brashear A, Mayer NH. New York: WE MOVE; 2008:119-141.
36. Lannin NA, Horsley SA, Herbert R, et al.: Splinting the hand in the functional position after brain impairment: A randomized, controlled trial. Arch Phys Med Rehabil 2003, 84:297-302.